Furthermore, antihormonal therapies with luteinizing hormone-releasing hormone (LHRH)-antagonists, tamoxifen, aromatase inhibitors, gonadotropin-releasing hormone (GnRH)-analogist leuprorelin, or the progesterone derivate megestrol show good responses in recurring oestrogen secreting tumours [20, 40]. This evidence concerns the gene GNRH1 and neoplasm.